ГоловнаArchive of numbers2015Volume 23, issue 4 (85)Neurocognitive defi cit in patients with schizophrenia and options for its correction
Title of the article Neurocognitive defi cit in patients with schizophrenia and options for its correction
Authors Tsona Andriy
In the section HELP TO PRACTICAL PHYSICIAN
Year 2015 Issue Volume 23, issue 4 (85) Pages 124-127
Type of article Scientific article Index UDK 616.895.8-06:616.89-008.45]-08 Index BBK -
Abstract This article is devoted to the topical problem of searching for strategies of neurocognitive deviations correction in patients with schizophrenia. In accordance with investigative hypothesis, that neurocognitive defi cit may be related to neurotrophic peptides defi ciency which causes synaptic destabilization, violation of synaptic connections, structural and molecular changes in the hippocampus, amygdala and prefrontal cortex of patients with schizophrenia, the method of Cerebrolysin administration for neurocognitive deficit correction has been proposed. Psychodiagnostic examination was conducted using neurocognitive tests (TMT A, WMS-III Spatial Span, UM Letter-Number Span, BACS Symbol Coding, HVLT-R) before and after treatment with Cerebrolysin. As a result, patients from the study sample had signifi cant improvement of quality of performance on TMT A, WMS-III Spatial Span, BACS Symbol Coding, HVLT-R tests. Despite some limitations of the research, promise for further research and the use of the neuropeptide substances (cerebrolysin) for neurocognitive defi cit correction in patients with schizophrenia was shown. Particularly, considering increasing eff orts in search for nontransmitter strategies of neurocognitive defi cit correction.
Key words schizophrenia, neurocognitive defi cits, neuropeptides, neurotrophic factors, cerebrolysin
Access to full text version of the article pdf download
Bibliography 1. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents / [M. Davidson, A. Reichenberg, J. Rabinowitz et al.] // Am. J. Psychiatry. — 1999. — Vol. 156. — P. 1328—1335. 2. Static and Dynamic Cognitive Deficits in Childhood Preceding Adult Schizophrenia: A 30-Year Study / [A. Reichenberg, A. Caspi, H. Harrington et al.] // Ibid. — 2010. — Vol. 167(2). — P. 160—169. 3. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates / [R. M. Bilder, R. S. Goldman, D. Robinson et al.] // Ibid. — 2000. — Vol. 157. — P. 549—559. 4. Rund, B. R. A review of longitudinal studies of cognitive functions in schizophrenia patients / B. R. Rund // Schizophr Bull. — 1998. — Vol. 24. — P. 425—435. 5. Bowie, C. R. Cognitive deficits and functional outcome in schizophrenia / C. R. Bowie, P. D. Harvey // Neuropsychiatr. Dis. Treat. — 2006. — Vol. 2(4) — P. 531—536. 6. Green, M. F. What are the functional consequences of neurocognitive deficits in schizophrenia? / M. F. Green // Am. J. Psychiatry. — 1996. — Vol. 153(3). — P. 321—330. 7. The relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenic patients / [J. D. Evans, R. K. Heaton, J. S. Paulsen et al.] // Biological Psychiatry. — 2003. — Vol. 53. — P. 422—430. 8. Identification of separable cognitive factors in schizophrenia / [K. H. Nuechterlein, D. M. Barch, J. M. Gold et al.] // Schizophr. Res. — 2004. — Vol. 72. — P. 29—39. 9. Usefulness of the UCSD Performance-based Skills Assessment (UPSA) for predicting residential independence in patients with chronic schizophrenia / [B. T. Mausbach, C. R. Bowie, P. D. Harvey et al.] // J. Psychiatr. Res. — 2008. — Vol. 42. — P. 320—327. 10. Leung, W. W. Functional implications of neuropsychological normality and symptom remission in older outpatients diagnosed with schizophrenia: A cross-sectional study / W. W. Leung, C. R. Bowie, P. D. Harvey // J. Int. Neuropsychol. Soc. — 2008. — Vol. 14. — P. 479—488. 11. One hundred years of schizophrenia: a meta-analysis of the outcome literature / [J. D. Hegarty, R. J. Baldessarini, M. Tohen et al.] // Am. J. Psychiatry. — 1994. — Vol. 151(10). — P. 1409—1416. 12. Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open- Label Clinical Trial (EUFEST) / [M. Davidson, S. Galderisi, M. Weiser et al.] // Ibid. — 2009. — Vol. 166. — P. 675—682. 13. Harvey, P. D. Pharmacological cognitive enhancement in schizophrenia / P. D. Harvey // Neuropsychol. Rev. — 2009. — Vol. 19. — P. 324—335. 14. Barch, D. M. Pharmacological strategies for enhancing cognition in schizophrenia / D. M. Barch // Curr. Topics. Behav. Neurosci. — 2010. — Vol. 4. — P. 43—96. 15. Harvey P. D. Cognitive Enhancement in Schizophrenia: Pharmacological and Cognitive Remediation Approaches / P. D. Harvey, C. R. Bowie // Psychiatr. Clin. North. Am. — 2012. — Vol. 35. — P. 683—698. 16. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia / [D. C. Javitt, R. W. Buchanan, R. S. Keefe et al.] // Schizophr. Res. — 2012. — Vol. 136(1—3). — P. 25—31. 17. The Dendritic Architecture of Prefrontal Pyramidal Neurons in Schizophrenic Patients / [P. Kalus, T. J. Müller, W. Zuschratter, D. Senitz] // NeuroReport. — 2000. — Vol. 11. — P. 3621—3625. 18. Nerve Growth Factor and Brain-Derived Neurotrophic Factor Concentrations in Schizophrenia: A Review / [G. Martinotti, G. Di Iorio, S. Marini et al.] // Journal of Biological Regulators and Homeostatic Agents. — 2012. — Vol. 26. — P. 347—356. 19. Moises, H. W. The glial growth factors deficiency and synaptic destabilization hypothesis of schizophrenia / H. W. Moises, T. Zoega, I. I. Gottesman // BMC Psychiatry. — 2002. — 2: 8. — P. 1—14. 20. Chronic Administration of the Neurotrophic Agent (Cerebrolysin) Ameliorated the Behavioral and Morphological Changes Induced by Neonatal Ventral Hippocampus Lesion in the Rat / [R. A. Vázquez- Roque, B. Ramos, C. Tecuatl et al.] // Journal Neuroscience Research. — 2012. — Vol. 90. — P. 288—306. 21. Masliah, E. The Pharmacology of Neurotrophic Treatment with Cerebrolysin: Brain Protection and Repair to Counteract Pathologies of Acute and Chronic Neurological Disorders / E. Masliah, E. Diez- Tejedor // Drugs of Today. — 2012. — Vol. 48. — P. 3—24. 22. Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms / [S. Xiao, H. Xue, G. Li et al.] // Aust. N. Z. J. Psychiatry. — 2012. — Vol. 46(2). — P. 153—160. 23. Flores, G. The Potential of Cerebrolysin in the Treatment of Schizophrenia / G. Flores, M. Atzori // Pharmacology & Pharmacy. — 2014. — Vol. 5(7). — P. 691—704. 24. Connectivity, Pharmacology, and Computation: Toward a Mechanistic Understanding of Neural System Dysfunction in Schizophrenia / [A. Anticevic, M. W. Cole, G. Repovs et al.] // Frontiers in Psychiatry. — 2013. — Vol. 4. — P. 1—21. 25. Шамсиев, А. Т. Сравнительный анализ применения вы- соких и низких доз церебролизина у больных резидуальной шизо фре нией / А. Т. Шамсиев, В. В. Каминский, Н. И. Ходжаева // Международный неврологический журнал. — 2008. — № 5(21).